Dienstag, 26. Januar 2021
Navigation öffnen

SchwerpunktDezember 2020

03. Dezember 2020
Seite 7/7




(1) Yadav D, Timmons L, Benson JT, Dierkhising RA, Chari ST. Incidence, prevalence, and survival of chronic pancreatitis: a population-based study. Am J Gastroenterol 2011; 106(12):2192–9.
(2) Yadav D, Whitcomb DC. The role of alcohol and smoking in pancreatitis. Nat Rev Gastroenterol Hepatol 2010; 7(3):131–45.
(3) S3-Leitlinie Chronische Pankreatitis. Stand 31.08.2012 (in Überarbeitung). https://www.awmf.org/leitlinien/detail/ll/021-003.html.
(4) Conwell DL, Banks PA, Sandhu BS, Sherman S, Al-Kaade S, Gardner TB et al. Validation of Demographics, Etiology, and Risk Factors for Chronic Pancreatitis in the USA: A Report of the North American Pancreas Study (NAPS) Group. Dig Dis Sci 2017; 62(8):2133–40.
(5) Yadav D, Hawes RH, Brand RE, Anderson MA, Money ME, Banks PA et al. Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. Arch Intern Med 2009; 169(11):1035–45.
(6) Lankisch PG, Lowenfels AB, Maisonneuve P. What is the risk of alcoholic pancreatitis in heavy drinkers? Pancreas 2002; 25(4):411–2.
(7) Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 2010; 24(3):349–58.
(8) Maisonneuve P, Lowenfels AB, Müllhaupt B, Cavallini G, Lankisch PG, Andersen JR et al. Cigarette smoking accelerates progression of alcoholic chronic pancreatitis. Gut 2005; 54(4):510–4.
(9) Talamini G, Bassi C, Falconi M, Sartori N, Vaona B, Bovo P et al. Smoking cessation at the clinical onset of chronic pancreatitis and risk of pancreatic calcifications. Pancreas 2007; 35(4):320–6.
(10) Schulte A, Pandeya N, Tran B, Fawcett J, Fritschi L, Risch HA et al. Cigarette smoking and pancreatic cancer risk: more to the story than just pack-years. Eur J Cancer 2014; 50(5):997–1003.
(11) Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011; 40(3):352–8.
(12) Kleger A, Seufferlein T, Wagner M, Tannapfel A, Hoffmann TK, Mayerle J. IgG4-related autoimmune diseases: Polymorphous presentation complicates diagnosis and treatment. Dtsch Arztebl Int 2015; 112(8):128–35.
(13) Rebours V, Boutron-Ruault M-C, Schnee M, Férec C, Le Maréchal C, Hentic O et al. The natural history of hereditary pancreatitis: a national series. Gut 2009; 58(1):97–103.
(14) Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clinical Gastroenterology and Hepatology 2004; 2(3):252–61.
(15) Kereszturi E, Szmola R, Kukor Z, Simon P, Weiss FU, Lerch MM et al. Hereditary pancreatitis caused by mutation-induced misfolding of human cationic trypsinogen: a novel disease mechanism. Hum Mutat 2009; 30(4):575–82.
(16) Zator Z, Whitcomb DC. Insights into the genetic risk factors for the development of pancreatic disease. Therap Adv Gastroenterol 2017; 10(3):323–36.
(17) Solomon S, Whitcomb DC. Genetics of pancreatitis: an update for clinicians and genetic counselors. Curr Gastroenterol Rep 2012; 14(2):112–7.
(18) Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998; 339(10):653–8.
(19) Whitcomb DC. Genetic aspects of pancreatitis. Annu Rev Med 2010; 61:413–24.
(20) Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med 2016; 5(9):2649–56.
(21) Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67(1):7–30.
(22) Kirkegård J, Mortensen FV, Cronin-Fenton D. Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. Am J Gastroenterol 2017; 112(9):1366–72.
(23) Carrière C, Young AL, Gunn JR, Longnecker DS, Korc M. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem Biophys Res Commun 2009; 382(3):561–5.
(24) Dhar P, Kalghatgi S, Saraf V. Pancreatic cancer in chronic pancreatitis. Indian J Surg Oncol 2015; 6(1):57–62.
(25) Shelton CA, Umapathy C, Stello K, Yadav D, Whitcomb DC. Hereditary Pancreatitis in the United States: Survival and Rates of Pancreatic Cancer. Am J Gastroenterol 2018; 113(9):1376.
(26) Lowenfels AB, Sullivan T, Fiorianti J, Maisonneuve P. The epidemiology and impact of pancreatic diseases in the United States. Curr Gastroenterol Rep 2005; 7(2):90–5.
(27) Lowenfels AB, Maisonneuve P, Dimagno EP, Elitsur Y, Gates LK, Perrault J et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997; 89(6):442–6.
(28) Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clinical Gastroenterology and Hepatology 2004; 2(3):252–61.
(29) Rebours V, Boutron-Ruault M-C, Jooste V, Bouvier A-M, Hammel P, Ruszniewski P et al. Mortality rate and risk factors in patients with hereditary pancreatitis: uni- and multidimensional analyses. Am J Gastroenterol 2009; 104(9):2312–7.
(30) Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011; 47(13):1928–37.
(31) Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134(4):981–7.
(32) Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159(12):1160–7.
(33) Chari ST, Leibson CL, Rabe KG, Ransom J, Andrade M de, Petersen GM. Probability of Pancreatic Cancer Following Diabetes: A Population-Based Study. Gastroenterology 2005; 129(2):504–11.
(34) Gardner TB, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol 2020; 115(3):322–39.
(35) Catalano MF, Sahai A, Levy M, Romagnuolo J, Wiersema M, Brugge W et al. EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. Gastrointest Endosc 2009; 69(7):1251–61.
(36) Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algül H, Friess H et al. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Theranostics 2019; 9(5):1280–7.
(37) Dominguez-Munoz JE, Drewes AM, Lindkvist B, Ewald N, Czakó L, Rosendahl J et al. Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis. Pancreatology 2018; 18(8):847–54.
(38) Perkhofer L, Besold T, Schmidberger J, Seufferlein T, Hann A, Müller M et al. Etiology and Morphology Impact on the Clinical Course of Chronic Pancreatitis. Digestion 2020:1–7.
(39) Machicado JD, Chari ST, Timmons L, Tang G, Yadav D. A population-based evaluation of the natural history of chronic pancreatitis. Pancreatology 2018; 18(1):39–45.
(40) Ahmed Ali U, Jens S, Busch ORC, Keus F, van Goor H, Gooszen HG et al. Antioxidants for pain in chronic pancreatitis. Cochrane Database Syst Rev 2014; (8):CD008945.
(41) Gardner TB, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol 2020; 115(3):322–39.
(42) Löhr JM, Dominguez-Munoz E, Rosendahl J, Besselink M, Mayerle J, Lerch MM et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J 2017; 5(2):153–99.
(43) Andrén-Sandberg A, Dervenis C, Lowenfels B. Etiologic links between chronic pancreatitis and pancreatic cancer. Scand J Gastroenterol 1997; 32(2):97–103.
(44) Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25(18):2607–15.
(45) Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364(19):1817–25.
(46) Vogel A, Römmler-Zehrer J, Li JS, McGovern D, Romano A, Stahl M. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer 2016; 16(1):817.
(47) Schneider A, Barmada MM, Slivka A, Martin JA, Whitcomb DC. Clinical characterization of patients with idiopathic chronic pancreatitis and SPINK1 Mutations. Scand J Gastroenterol 2004; 39(9):903–4.
(48) Witt H, Luck W, Hennies HC, Classen M, Kage A, Lass U et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000; 25(2):213–6.
(49) Schneider A, Larusch J, Sun X, Aloe A, Lamb J, Hawes R et al. Combined bicarbonate conductance-impairing variants in CFTR and SPINK1 variants are associated with chronic pancreatitis in patients without cystic fibrosis. Gastroenterology 2011; 140(1):162–71.
(50) Fink EN, Kant JA, Whitcomb DC. Genetic counseling for nonsyndromic pancreatitis. Gastroenterol Clin North Am 2007; 36(2):325-33, ix.
(51) Pfützer RH, Barmada MM, Brunskill AP, Finch R, Hart PS, Neoptolemos J et al. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 2000; 119(3):615–23.
(52) Kleeff J, Whitcomb DC, Shimosegawa T, Esposito I, Lerch MM, Gress T et al. Chronic pancreatitis. Nat Rev Dis Primers 2017; 3:17060.

Nächste Seite


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Chronische Pankreatitis: Risikofaktor für Pankreaskarzinome"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der Medical Tribune Verlagsgesellschaft mbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: info[at]rsmedia-verlag.de.

  • COVID-19-Impfstoffkandidat JNJ-78436735 zur 1x-Gabe: Interimsdaten der Phase 1/2a
  • COVID-19-Impfstoffkandidat JNJ-78436735 zur 1x-Gabe: Interimsdaten der Phase 1/2a